Carmell Therapeutics Corporation (CTCX) Stock
CTCX is no longer traded. Carmell Therapeutics was delisted from the Nasdaq in March 2025.
Prices on this page are historical; the last trade was March 7, 2025 at $0.20.
Carmell Therapeutics stock price history
CTCX final trading statistics
- Final close
- $0.20
- Final trading day
- Mar 7, 2025
- Market cap at delisting
- $5.94M
- Shares outstanding
- 30.12M
- Final 52-week range
- $0.17 – $3.05
- Avg. volume (final 3 mo.)
- 6,917,576
- All-time high (split-adj.)
- $11.00 · Jul 2023
- All-time low (split-adj.)
- $0.19 · Mar 2025
- Return since IPO
- -98.0%
- Beta
- 0.51
- Book value / share
- -$0.19
- Price / book
- -1.02
Carmell Therapeutics annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2024 | $50.3K | -$10.4M | — |
| FY2023 | $0.00 | -$15.4M | — |
| FY2022 | $0.00 | -$9.1M | $0.02 |
| FY2021 | $0.00 | -$6.5M | -$0.02 |
Last five fiscal years reported before the delisting; fiscal year ending December. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.
About Carmell Therapeutics Corporation
Carmell Corporation operates as a bio-aesthetics company. The company utilizes Carmell Secretome to support skin and hair health. Its Carmell Secretome consists of growth factors and proteins extracted from allogeneic human platelets sourced from tissue banks. The company also developed a microemulsion formulation that enables delivery of lipophilic and hydrophilic ingredients without relying on the Foul Fourteen, 14 potentially harmful excipients that are commonly used by other companies to impart texture, stability, and other desirable physicochemical attributes to cosmetic products. In addition, the company is also developing a line of men's products and a line of topical haircare products. It has licensing agreement with Carnegie Mellon University to develop and commercialize biocompatible plasma-based plastics. The company was formerly known as Carmell Therapeutics Corporation and changed its name to Carmell Corporation in November 2023. Carmell Therapeutics Corporation was founded in 2008 and is headquartered in Pittsburgh, Pennsylvania.
Carmell Therapeutics stock FAQ
What happened to Carmell Therapeutics stock?
Carmell Therapeutics stock was delisted from the Nasdaq. Its final close was $0.20 on March 7, 2025.
Is CTCX stock still trading?
No. CTCX was delisted from the Nasdaq in March 2025 and no longer trades on a U.S. exchange.
What was the last price of CTCX stock?
CTCX closed at $0.20 on its final trading day, March 7, 2025, for a market value of about $5.94M.
What were Carmell Therapeutics's revenue and earnings in its last full fiscal year?
Carmell Therapeutics reported revenue of $50.3K and net income of -$10.4M in fiscal 2024, its last full year as a public company.
When did Carmell Therapeutics go public?
Carmell Therapeutics Corporation stock began trading on July 17, 2023.